パージェタの市場規模、シェア、動向分析レポート：製品別、適応症別、流通チャネル別、地域別、セグメント予測、2025年～2030年

パージェタ市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のパージェタ市場は2030年までに59億3,000万米ドルに達すると予測され、2025年から2030年までのCAGRは5.5%で成長すると予測されています。

F.ホフマン・ラ・ロシュ社が開発したモノクローナル抗体であるパージェタ（ペルツズマブ）の市場は、HER2陽性乳がんの治療、特に早期乳がんや転移性乳がんの治療において強い勢いを示し続けています。併用療法の一環として、パージェタはネオアジュバントおよび転移性治療レジメンの両方で治療成績の改善を示し、包括的乳がん治療におけるその役割を確固たるものにしています。HER2受容体を標的としてがん細胞の増殖を抑制するという作用機序により、この薬剤は最新の腫瘍学プロトコールの要となっています。

パージェタは、トラスツズマブや化学療法と併用されるのが一般的であり、早期乳がんにおける再発リスクの低減や転移症例における無増悪生存期間の延長におけるその有効性は、確固たる臨床データによって裏付けられています。乳がん罹患率の継続的な上昇に加え、認知度の向上と早期診断への取り組みが、パージェタのような効果的な生物学的製剤に対する需要の増加を後押ししています。

パージェタの流通において、病院薬局は依然として中心的な役割を担っており、特に治療初期には医師の監督と輸液インフラが必要です。ペイシェントジャーニーの治療が進むにつれて、専門薬局は、輸液調整、個別化ケアマネジメント、アドヒアランスサポートなど、がん患者に合わせたサービスを提供することで、その役割を拡大しています。このような薬局は、複雑な生物学的製剤治療を受ける患者が一貫した治療へのアクセスを維持できるよう支援しています。

現在、パージェタは先発品ですが、将来的にジェネリック医薬品やバイオシミラー医薬品が導入されれば、市場が大きく変わる可能性があります。より費用対効果の高い代替薬が利用できるようになれば、アクセシビリティが向上し、長期のがん治療に伴う経済的負担が軽減されます。これは、特に新興市場や、技術革新と手頃な価格の両立を迫られている医療制度に大きな影響を与えると思われます。

他の生物学的製剤と同様、サプライチェーンの効率化とコールドチェーン物流は、医薬品の品質と入手可能性を維持するために引き続き重要です。専門薬局やオンライン薬局の役割の増大は、デジタルヘルスや患者管理プラットフォームの進歩と相まって、こうした課題を克服し、全体的な患者体験を向上させる機会を提供しています。

パージェタのような先進的な治療薬に対する需要は、腫瘍学における精密医療への幅広いシフトを反映しています。乳がんは世界的に最も罹患率の高いがんの1つであり、標的を絞った効果的な治療オプションに対するニーズはかつてないほど高まっています。F.ホフマン・ラ・ロシュ社のような企業による継続的な技術革新は、病院や薬局のネットワークにわたる戦略的パートナーシップとともに、この需要に応え、世界の乳がん患者の転帰を改善する上で鍵となるであろう。

Perjeta市場レポートハイライト

• 製品別では、モノクローナル抗体セグメントが2024年の市場を席巻し、乳がん治療の優先選択肢としての地位を固めました。Perjetaは標的モノクローナル抗体治療薬であり、HER2陽性乳がんに対して高い特異性と有効性を示し、この市場セグメントで支配的な薬剤クラスとなっています。
• 適応症別では、転移性乳がん領域が2024年のパージェタ市場を独占しました。転移性HER2陽性乳がんにおける無増悪生存期間および全生存期間を延長することが証明されていることから、この適応症がPerjetaの需要を牽引しています。
• 流通チャネルに基づくと、2024年には病院薬局が支配的な流通チャネルとして浮上しました。静脈内投与と綿密な医学的管理が必要なため、病院薬局がパージェタの主な流通チャネルとなっています。
• 北米がパージェタ市場を牽引したのは、医療インフラが整備されていること、疾患に対する認知度が高いこと、先進的な治療選択肢があることなどが要因です。同地域は研究とイノベーションに力を入れており、市場の成長をさらに後押ししています。
• パージェタ市場に参入している企業には、F. Hoffmann-La Roche Ltd、Ambrx Biopharma、Carisma Therapeutics、Byondisなどがあります。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 パージェタ市場の変数、動向、範囲

• 市場系統の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• ビジネス環境分析
  • 業界分析- ポーターのファイブフォース分析
  • PESTLE分析
  • パイプライン分析
  • 特許満了分析
  • 価格分析

第4章 パージェタ市場：製品ビジネス分析

• 製品市場シェア、2024年と2030年
• 製品セグメントダッシュボード
• 市場規模、予測、動向分析（製品別、2018～2030年）
• モノクローナル抗体
• ジェネリック医薬品

第5章 パージェタ市場：適応症ビジネス分析

• 適応症市場シェア、2024年および2030年
• 適応症セグメントダッシュボード
• 市場規模、予測、動向分析（適応症別、2018～2030年）
• 早期乳がん
• 転移性乳がん

第6章 パージェタ市場：流通チャネルのビジネス分析

• 流通チャネル市場シェア、2024年および2030年
• 流通チャネルセグメントダッシュボード
• 市場規模、予測、動向分析（流通チャネル別、2018～2030年）
• 病院薬局
• 専門薬局
• その他の薬局

第7章 パージェタ市場：地域の推定・動向分析

• 地域市場シェア分析、2024年および2030年
• 地域市場ダッシュボード
• 市場規模と予測動向分析、2018年から2030年
• 北米
  • 国別、2018年～2030年
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東およびアフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 参入企業概要
• 企業の市況分析
• 企業分類
• 戦略マッピング
• 企業プロファイル/リスト
  • F. Hoffmann-La Roche Ltd
  • Ambrx Biopharma
  • Carisma Therapeutics
  • Byondis

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 Global Perjeta market, by region, 2018 - 2030 (USD Million)
• Table 4 Global Perjeta market, by product, 2018 - 2030 (USD Million)
• Table 5 Global Perjeta market, by indication, 2018 - 2030 (USD Million)
• Table 6 Global Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
• Table 7 North America Perjeta market, by country, 2018 - 2030 (USD Million)
• Table 8 North America Perjeta market, by product, 2018 - 2030 (USD Million)
• Table 9 North America Perjeta market, by indication, 2018 - 2030 (USD Million)
• Table 10 North America Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
• Table 11 U.S. Perjeta market, by product, 2018 - 2030 (USD Million)
• Table 12 U.S. Perjeta market, by indication, 2018 - 2030 (USD Million)
• Table 13 U.S. Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
• Table 14 Canada Perjeta market, by product, 2018 - 2030 (USD Million)
• Table 15 Canada Perjeta market, by indication, 2018 - 2030 (USD Million)
• Table 16 Canada Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
• Table 17 Mexico Perjeta market, by product, 2018 - 2030 (USD Million)
• Table 18 Mexico Perjeta market, by indication, 2018 - 2030 (USD Million)
• Table 19 Mexico Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
• Table 20 Europe Perjeta market, by country, 2018 - 2030 (USD Million)
• Table 21 Europe Perjeta market, by product, 2018 - 2030 (USD Million)
• Table 22 Europe Perjeta market, by indication, 2018 - 2030 (USD Million)
• Table 23 Europe Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
• Table 24 UK Perjeta market, by product, 2018 - 2030 (USD Million)
• Table 25 UK Perjeta market, by indication, 2018 - 2030 (USD Million)
• Table 26 UK Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
• Table 27 Germany Perjeta market, by product, 2018 - 2030 (USD Million)
• Table 28 Germany Perjeta market, by indication, 2018 - 2030 (USD Million)
• Table 29 Germany Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
• Table 30 France Perjeta market, by product, 2018 - 2030 (USD Million)
• Table 31 France Perjeta market, by indication, 2018 - 2030 (USD Million)
• Table 32 France Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
• Table 33 Italy Perjeta market, by product, 2018 - 2030 (USD Million)
• Table 34 Italy Perjeta market, by indication, 2018 - 2030 (USD Million)
• Table 35 Italy Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
• Table 36 Spain Perjeta market, by product, 2018 - 2030 (USD Million)
• Table 37 Spain Perjeta market, by indication, 2018 - 2030 (USD Million)
• Table 38 Spain Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
• Table 39 Norway Perjeta market, by product, 2018 - 2030 (USD Million)
• Table 40 Norway Perjeta market, by indication, 2018 - 2030 (USD Million)
• Table 41 Norway Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
• Table 42 Denmark Perjeta market, by product, 2018 - 2030 (USD Million)
• Table 43 Denmark Perjeta market, by indication, 2018 - 2030 (USD Million)
• Table 44 Denmark Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
• Table 45 Sweden Perjeta market, by product, 2018 - 2030 (USD Million)
• Table 46 Sweden Perjeta market, by indication, 2018 - 2030 (USD Million)
• Table 47 Sweden Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
• Table 48 Asia Pacific Perjeta market, by country, 2018 - 2030 (USD Million)
• Table 49 Asia Pacific Perjeta market, by product, 2018 - 2030 (USD Million)
• Table 50 Asia Pacific Perjeta market, by indication, 2018 - 2030 (USD Million)
• Table 51 Asia Pacific Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
• Table 52 Japan Perjeta market, by product, 2018 - 2030 (USD Million)
• Table 53 Japan Perjeta market, by indication, 2018 - 2030 (USD Million)
• Table 54 Japan Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
• Table 55 China Perjeta market, by product, 2018 - 2030 (USD Million)
• Table 56 China Perjeta market, by indication, 2018 - 2030 (USD Million)
• Table 57 China Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
• Table 58 India Perjeta market, by product, 2018 - 2030 (USD Million)
• Table 59 India Perjeta market, by indication, 2018 - 2030 (USD Million)
• Table 60 India Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
• Table 61 Australia Perjeta market, by product, 2018 - 2030 (USD Million)
• Table 62 Australia Perjeta market, by indication, 2018 - 2030 (USD Million)
• Table 63 Australia Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
• Table 64 South Korea Perjeta market, by product, 2018 - 2030 (USD Million)
• Table 65 South Korea Perjeta market, by indication, 2018 - 2030 (USD Million)
• Table 66 South Korea Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
• Table 67 Thailand Perjeta market, by product, 2018 - 2030 (USD Million)
• Table 68 Thailand Perjeta market, by indication, 2018 - 2030 (USD Million)
• Table 69 Thailand Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
• Table 70 Latin America Perjeta market, by country, 2018 - 2030 (USD Million)
• Table 71 Latin America Perjeta market, by product, 2018 - 2030 (USD Million)
• Table 72 Latin America Perjeta market, by indication, 2018 - 2030 (USD Million)
• Table 73 Latin America Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
• Table 74 Brazil Perjeta market, by product, 2018 - 2030 (USD Million)
• Table 75 Brazil Perjeta market, by indication, 2018 - 2030 (USD Million)
• Table 76 Brazil Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
• Table 77 Argentina Perjeta market, by product, 2018 - 2030 (USD Million)
• Table 78 Argentina Perjeta market, by indication, 2018 - 2030 (USD Million)
• Table 79 Argentina Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
• Table 80 Middle East & Africa Perjeta market, by country, 2018 - 2030 (USD Million)
• Table 81 Middle East & Africa Perjeta market, by product, 2018 - 2030 (USD Million)
• Table 82 Middle East & Africa Perjeta market, by indication, 2018 - 2030 (USD Million)
• Table 83 Middle East & Africa Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
• Table 84 South Africa Perjeta market, by product, 2018 - 2030 (USD Million)
• Table 85 South Africa Perjeta market, by indication, 2018 - 2030 (USD Million)
• Table 86 South Africa Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
• Table 87 Saudi Arabia Perjeta market, by product, 2018 - 2030 (USD Million)
• Table 88 Saudi Arabia Perjeta market, by indication, 2018 - 2030 (USD Million)
• Table 89 Saudi Arabia Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
• Table 90 UAE Perjeta market, by product, 2018 - 2030 (USD Million)
• Table 91 UAE Perjeta market, by indication, 2018 - 2030 (USD Million)
• Table 92 UAE Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
• Table 93 Kuwait Perjeta market, by product, 2018 - 2030 (USD Million)
• Table 94 Kuwait Perjeta market, by indication, 2018 - 2030 (USD Million)
• Table 95 Kuwait Perjeta market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Perjeta market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Therapeutic approach and application outlook (USD Million)
• Fig. 10 Competitive landscape
• Fig. 11 Perjeta market dynamics
• Fig. 12 Perjeta market: Porter's five forces analysis
• Fig. 13 Perjeta market: PESTLE analysis
• Fig. 14 Product market, 2018 - 2030 (USD Million)
• Fig. 15 Monoclonal antibody market, 2018 - 2030 (USD Million)
• Fig. 16 Generic drug market, 2018 - 2030 (USD Million)
• Fig. 17 Indication market, 2018 - 2030 (USD Million)
• Fig. 18 Early breast cancer market, 2018 - 2030 (USD Million)
• Fig. 19 Metastatic breast cancer market, 2018 - 2030 (USD Million)
• Fig. 20 Distribution channel market, 2018 - 2030 (USD Million)
• Fig. 21 Hospital pharmacies market, 2018 - 2030 (USD Million)
• Fig. 22 Specialty pharmacies market, 2018 - 2030 (USD Million)
• Fig. 23 Online pharmacies market, 2018 - 2030 (USD Million)
• Fig. 24 Perjeta market revenue, by region
• Fig. 25 Regional marketplace: Key takeaways
• Fig. 26 North America Perjeta market, 2018 - 2030 (USD Million)
• Fig. 27 U.S. country dynamics
• Fig. 28 U.S. Perjeta market, 2018 - 2030 (USD Million)
• Fig. 29 Canada country dynamics
• Fig. 30 Canada Perjeta market, 2018 - 2030 (USD Million)
• Fig. 31 Mexico country dynamics
• Fig. 32 Mexico Perjeta market, 2018 - 2030 (USD Million)
• Fig. 33 Europe Perjeta market, 2018 - 2030 (USD Million)
• Fig. 34 UK country dynamics
• Fig. 35 UK Perjeta market, 2018 - 2030 (USD Million)
• Fig. 36 Germany country dynamics
• Fig. 37 Germany Perjeta market, 2018 - 2030 (USD Million)
• Fig. 38 France country dynamics
• Fig. 39 France Perjeta market, 2018 - 2030 (USD Million)
• Fig. 40 Italy country dynamics
• Fig. 41 Italy Perjeta market, 2018 - 2030 (USD Million)
• Fig. 42 Spain country dynamics
• Fig. 43 Spain Perjeta market, 2018 - 2030 (USD Million)
• Fig. 44 Norway country dynamics
• Fig. 45 Norway Perjeta market, 2018 - 2030 (USD Million)
• Fig. 46 Sweden country dynamics
• Fig. 47 Sweden Perjeta market, 2018 - 2030 (USD Million)
• Fig. 48 Denmark country dynamics
• Fig. 49 Denmark Perjeta market, 2018 - 2030 (USD Million)
• Fig. 50 Asia Pacific Perjeta market, 2018 - 2030 (USD Million)
• Fig. 51 Japan country dynamics
• Fig. 52 Japan Perjeta market, 2018 - 2030 (USD Million)
• Fig. 53 China country dynamics
• Fig. 54 China Perjeta market, 2018 - 2030 (USD Million)
• Fig. 55 India country dynamics
• Fig. 56 India Perjeta market, 2018 - 2030 (USD Million)
• Fig. 57 Australia country dynamics
• Fig. 58 Australia Perjeta market, 2018 - 2030 (USD Million)
• Fig. 59 South Korea country dynamics
• Fig. 60 South Korea Perjeta market, 2018 - 2030 (USD Million)
• Fig. 61 Thailand country dynamics
• Fig. 62 Thailand Perjeta market, 2018 - 2030 (USD Million)
• Fig. 63 Latin America Perjeta market, 2018 - 2030 (USD Million)
• Fig. 64 Brazil country dynamics
• Fig. 65 Brazil Perjeta market, 2018 - 2030 (USD Million)
• Fig. 66 Argentina country dynamics
• Fig. 67 Argentina Perjeta market, 2018 - 2030 (USD Million)
• Fig. 68 MEA Perjeta market, 2018 - 2030 (USD Million)
• Fig. 69 South Africa country dynamics
• Fig. 70 South Africa Perjeta market, 2018 - 2030 (USD Million)
• Fig. 71 Saudi Arabia country dynamics
• Fig. 72 Saudi Arabia Perjeta market, 2018 - 2030 (USD Million)
• Fig. 73 UAE country dynamics
• Fig. 74 UAE Perjeta market, 2018 - 2030 (USD Million)
• Fig. 75 Kuwait country dynamics
• Fig. 76 Kuwait Perjeta market, 2018 - 2030 (USD Million)
• Fig. 77 Company categorization
• Fig. 78 Company market position analysis, 2024
• Fig. 79 Strategic framework

Perjeta Market Growth & Trends:

The global perjeta market is anticipated to reach USD 5.93 billion by 2030 and is projected to grow at a CAGR of 5.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market for Perjeta (pertuzumab), a monoclonal antibody developed by F. Hoffmann-La Roche Ltd, continues to show strong momentum in the treatment of HER2-positive breast cancer, particularly in early-stage and metastatic settings. As part of combination therapies, Perjeta has demonstrated improved outcomes in both neoadjuvant and metastatic treatment regimens, solidifying its role in comprehensive breast cancer care. The drug's mechanism of action-targeting the HER2 receptor to inhibit cancer cell growth-has made it a cornerstone in modern oncology protocols.

Perjeta is commonly used in conjunction with trastuzumab and chemotherapy, and its efficacy in reducing the risk of disease recurrence in early breast cancer, as well as extending progression-free survival in metastatic cases, has been backed by robust clinical data. The continued rise in breast cancer incidence, along with growing awareness and early diagnosis initiatives, is driving increased demand for effective biologic therapies such as Perjeta.

Hospital pharmacies remain central to Perjeta's distribution, particularly during the initial phases of treatment, where medical supervision and infusion infrastructure are necessary. As patients progress through their treatment journey, specialty pharmacies play a growing role by offering services tailored to oncology patients, including infusion coordination, personalized care management, and adherence support. These pharmacies help ensure that patients undergoing complex biologic therapies maintain consistent access to treatment.

Although Perjeta is currently a branded therapy, the future introduction of a generic or biosimilar version could significantly reshape the market. The availability of more cost-effective alternatives would enhance accessibility and relieve some of the financial burden associated with long-term cancer treatment. This would be particularly impactful in emerging markets and health systems under pressure to balance innovation with affordability.

As with other biologic therapies, supply chain efficiency and cold chain logistics remain critical to maintaining drug quality and availability. The growing role of specialty and online pharmacies, combined with advancements in digital health and patient management platforms, offers opportunities to overcome these challenges and improve the overall patient experience.

The demand for advanced therapies like Perjeta reflects a broader shift toward precision medicine in oncology. With breast cancer remaining one of the most prevalent cancers worldwide, the need for targeted, effective treatment options is stronger than ever. Continued innovation by companies like F. Hoffmann-La Roche Ltd, along with strategic partnerships across hospital and pharmacy networks, will be key in meeting this demand and improving outcomes for breast cancer patients globally.

Perjeta Market Report Highlights:

• Based on product, the monoclonal antibody segment dominated the market in 2024, solidifying its position as the preferred treatment option for breast cancer management. Perjeta is a targeted monoclonal antibody therapy, offering high specificity and effectiveness against HER2-positive breast cancer, making it the dominant drug class in this market segment.
• Based on indication, metastatic breast cancer segment dominated the Perjeta market in 2024. Its proven ability to extend progression-free and overall survival in metastatic HER2-positive breast cancer makes this indication the primary driver of Perjeta's demand.
• Based on distribution channel, hsopital pharmacies emerged as the dominant distribution channel in 2024. Due to the need for intravenous administration and close medical supervision, hospital pharmacies are the main distribution channel for Perjeta.
• North America led the Perjeta market, attributed to factors such as a well-established healthcare infrastructure, high awareness of about disease, and the availability of advanced treatment options. The region's strong focus on research and innovation further supports market growth.
• Companies operating in the Perjeta market include F. Hoffmann-La Roche Ltd, Ambrx Biopharma, Carisma Therapeutics, and Byondis.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Indication
  • 1.2.3. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Perjeta Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
    • 3.3.3.1. Phase 1
    • 3.3.3.2. Phase 2
    • 3.3.3.3. Phase 3
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Perjeta Market: Product Business Analysis

• 4.1. Product Market Share, 2024 & 2030
• 4.2. Product Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Monoclonal Antibody
  • 4.4.1. Monoclonal Antibody Market, 2018 - 2030 (USD Million)
• 4.5. Generic Drug
  • 4.5.1. Generic Drug Market, 2018 - 2030 (USD Million)

Chapter 5. Perjeta Market: Indication Business Analysis

• 5.1. Indication Market Share, 2024 & 2030
• 5.2. Indication Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
• 5.4. Early Breast Cancer
  • 5.4.1. Early Breast Cancer Market, 2018 - 2030 (USD Million)
• 5.5. Metastatic Breast Cancer
  • 5.5.1. Metastatic Breast Cancer Market, 2018 - 2030 (USD Million)

Chapter 6. Perjeta Market: Distribution Channel Business Analysis

• 6.1. Distribution Channel Market Share, 2024 & 2030
• 6.2. Distribution Channel Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
• 6.4. Hospital Pharmacies
  • 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
• 6.5. Specialty Pharmacies
  • 6.5.1. Specialty Pharmacies Market, 2018 - 2030 (USD Million)
• 6.6. Other Pharmacies
  • 6.6.1. Other Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 7. Perjeta Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030
• 7.4. North America
  • 7.4.1. North America Perjeta Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Target Disease Prevalence
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Reimbursement Framework
    • 7.4.2.5. U.S. Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Target Disease Prevalence
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Reimbursement Framework
    • 7.4.3.5. U.S. Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Target Disease Prevalence
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Reimbursement Framework
    • 7.4.4.5. Mexico Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Target Disease Prevalence
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement Framework
    • 7.5.2.5. Uk Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Target Disease Prevalence
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement Framework
    • 7.5.3.5. Germany Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Target Disease Prevalence
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Reimbursement Framework
    • 7.5.4.5. France Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Target Disease Prevalence
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Reimbursement Framework
    • 7.5.5.5. Italy Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Target Disease Prevalence
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Reimbursement Framework
    • 7.5.6.5. Spain Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Target Disease Prevalence
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Reimbursement Framework
    • 7.5.7.5. Denmark Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Target Disease Prevalence
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Reimbursement Framework
    • 7.5.8.5. Sweden Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Target Disease Prevalence
    • 7.5.9.3. Regulatory Framework
    • 7.5.9.4. Reimbursement Framework
    • 7.5.9.5. Norway Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Target Disease Prevalence
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement Framework
    • 7.6.2.5. Japan Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Target Disease Prevalence
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement Framework
    • 7.6.3.5. China Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Target Disease Prevalence
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement Framework
    • 7.6.4.5. India Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Target Disease Prevalence
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement Framework
    • 7.6.5.5. Australia Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Target Disease Prevalence
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Reimbursement Framework
    • 7.6.6.5. South Korea Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Target Disease Prevalence
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Reimbursement Framework
    • 7.6.7.5. Thailand Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Target Disease Prevalence
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Reimbursement Framework
    • 7.7.2.5. Japan Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Target Disease Prevalence
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Reimbursement Framework
    • 7.7.3.5. China Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. Middle East and Africa
  • 7.8.1. Middle East and Africa Perjeta Market Estimates and Forecasts, 2017 - 2030 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Target Disease Prevalence
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Reimbursement Framework
    • 7.8.2.5. South Africa Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Target Disease Prevalence
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Reimbursement Framework
    • 7.8.3.5. Saudi Arabia Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Target Disease Prevalence
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. Reimbursement Framework
    • 7.8.4.5. UAE Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Target Disease Prevalence
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Reimbursement Framework
    • 7.8.5.5. Kuwait Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. F. Hoffmann-La Roche Ltd
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. Ambrx Biopharma
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Carisma Therapeutics
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Byondis
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives